The SGLT2 inhibitors – where are we now? (2017)

Type of publication:
Journal article

*Morris, David

Journal of Diabetes Nursing; Jun 2017; vol. 21 (no. 5); p. 162-167

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are once-daily oral agents effective in treating hyperglycaemia in people with type 2 diabetes, with additional benefits including weight loss and a low risk of hypoglycaemia. This review provides a basic guide to the SGLT2 inhibitors licensed in the UK, including their mechanism of action, benefits, adverse effects and limitations, and place in treatment. Advice on avoiding the rare but serious adverse effect of diabetic ketoacidosis is also provided.

Link to full-text: